Le Lézard
Classified in: Health, Business
Subjects: EARNINGS, CALENDAR OF EVENTS, Conference Calls/ Webcasts

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update


MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT.

Theratechnologies will also provide further information on the Complete Response Letter issued by the U.S. Food and Drug Administration in response to the Company's supplemental Biologics License Application for the F8 formulation of tesamorelin.

The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will be joined by other members of the management team, including Senior Vice President and Chief Financial Officer, Mr. Philippe Dubuc, Senior Vice President and Chief Medical Officer, Dr. Christian Marsolais and Global Commercial Officer, Mr. John Leasure, who will be available to answer questions from participants following prepared remarks.

Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below.

CONFERENCE CALL INFORMATION
Conference Call DateFebruary 21, 2024
Conference Call Time8:30 a.m. EDT
Webcast linkhttps://edge.media-server.com/mmc/p/6fyph854
Dial in1-888-317-6003 (toll free) or 1-412-317-6061 (international)
Access Code0664356
CONFERENCE CALL REPLAY
Toll Free1-877-344-7529 (US) / 1-855-669-9658 (Canada)
International Toll1-412-317-0088
Replay Access Code3842515
Replay End DateFebruary 28, 2024
To access the replay using an international dial-in number, please select this link:
https://services.choruscall.com/ccforms/replay.html


An archived webcast will also be available on the Company's Investor Relations website under ?Past Events'.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter). 

Contacts:

Philippe Dubuc
Senior Vice President and Chief Financial Officer
[email protected]
438-315-6608



These press releases may also interest you

at 18:44
Healthcare technology company RXNT, a leading developer of ambulatory clinical and practice management software, announced its successful transition to the Relay Exchange clearinghouse via Change Healthcare on May 9th, 2024. This...

at 18:32
Center for Lyme Action (CLA) and Generation Lyme are pleased to announce a new Community Partnership to leverage each nonprofit organization's distinct resources to support current and future Lyme disease advocates. This collaboration marks a...

at 18:18
LG Electronics announces the launch of the third season of its podcast, "Transparent Conversations," which brings conversations about mental health directly to college campuses around the country, with live tapings throughout the year at pivotal...

at 18:15
DaVita Inc.  today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at BofA Securities 2024 Health Care Conference on...

at 17:36
Georgia lawmakers recently approved approximately $11 million to support an adult dental benefit for people enrolled in Medicaid. This is the first step toward helping low-income adults with Medicaid coverage obtain routine oral health care. Prior to...

at 17:35
VitalHub Corp. (the "Company" or "VitalHub") announced today it has filed its Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis report for the three ended March 31, 2024, with the Canadian securities...



News published on and distributed by: